We are Sorry, This Page doesn't Exist

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Brainstorm Health Daily: April 16, 2018 Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be r.....»»

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Merck gained.....»»

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies......»»

Using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity.....»»

Brainstorm Health Daily: May 29, 2018 Hurricane season does not officially begin until Friday, June 1--though that start date is somewhat artificial as Subtropical Storm Alberto made clear yesterday--driving its way across .....»»

Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications. Pfi.....»»

KDALLung Cancer Drug From Merck Solidifies Lead in Crowded FieldBloombergIn the race to.....»»

Nektar Therapeutics lost a third of its value in Monday trading after response rates in melanoma and kidney cancer patients decreased in a mid-stage trial of the company’s cancer drug in combination with Bristol-Myers Squibb Co.’s Opdivo......»»

Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer. Br.....»»

A Boulder biotech's combination treatment for a form of skin cancer was approved this week by the U.S. Food and Drug Administration. Array BioPharma Inc. (Nasdaq: ARRY) said its Braftovi capsules in combination with Mektovi tablets has been approved .....»»

Shares of the biotech company Advaxis Inc. surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The clinical hol.....»»

Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS). Roche H.....»»

Bristol-Myers Squibb Co. said Friday the U.S. Food and Drug Admi.....»»

The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small ce.....»»